Vaxcyte is no longer a platform story waiting for a factory. The San Carlos vaccine developer finished dosing three adult Phase 3 studies of VAX-31, its broadest pneumococcal conjugate candidate, and handed a dedicated Lonza suite in Visp to commercial operations in early August. That handover closes a sequencing risk that had sat between a clean adult dataset and any license filing. The equity now prices a single immunogenicity table due in the fourth quarter, not a construction schedule.
Cash, cash equivalents and investments stood at $2,508 million at mid-year after a February underwritten sale. That raise brought in $602 million of net proceeds at $50 a share. Operating cash use in the first half reached $513 million, so the balance sheet is large and the burn is no longer theoretical. An unused at-the-market program of $500 million still sits as a backstop. The company can fund the adult readout, the infant dose-finding study, and a planned manufacturing-consistency lot without a forced raise, but only if spending stays near the current half-year pace.
The pivotal adult study dosed 4,049 participants against both current standard conjugates. Combined late-stage adult enrollment reached 6,191 people. The next several months decide whether that dataset supports a biologics license application or forces a redesign of the adult franchise. Does the serotype table clear a stricter noninferiority bar than the earlier adult study used, or does the market reprice a cash-rich developer that already built the plant?